永信 於湖北合資設立永瑞生技 破局!!

永信：補充公告101/3/23序號9「本公司代重要子公司永信藥品工業股份有限公司公告終止大陸永瑞合資案」 鉅亨網　　2012-05-04   第二條　第49款  1.事實發生日:101/05/04    2.公司名稱:永信藥品工業股份有限公司  3.與公司關係(請輸入本公司或聯屬公司):聯屬公司  4.相互持股比例:本公司百分之百持股子公司  5.發生緣由:  (1)永信藥品工業股份有限公司101/3/23董事會決議終止大陸投資永瑞生技有限公司。  (2)永瑞合資案因三方合資股東對於擴量生產之意見歧異未有共識，為避免影響   永信藥品工業股份有限公司營運，擬予終止合資案。  (3)經英屬維京群島YungRay Investment Co., Ltd. 101/05/04董事會通過三方合資終止   ，永信藥品工業股份有限公司正式與原合資案股東簽署終止合約。  6.因應措施:無  7.其他應敘明事項:補充公告本公司101/3/23序號9之公告。

永信於中國 原料藥廠投資 另謀對象!!

永信動物藥廠 大陸投資喊卡 【2012/05/05 經濟日報】   永信（3705）昨（4）日公告，旗下百分之百持股之永信藥品公司，將終止大陸永瑞生技公司投資案；  永信表示，中止投資案的主要原因為，三方對智財權的保護及擴量生產的意見分歧，永日、永信決定終止此合資公司的設立。永日則表達，在中國設立中間體、原料藥廠的方向不變，目前持續評估其他合作案。據了解，去年3月永日化學與永信控旗下永信藥品，及美國BRI宣布，將在大陸湖北合資設立永瑞生技，發展動物飼料添加劑及原料藥輔料，總投資額為800萬美金，其中永日與BRI各出資40%，永信藥品則出資20%。

喊卡! 永信於中國動物飼料添投資…

永信藥品：補充公告101/3/23「本公司公告終止透過第三地公司赴大陸　地區投資湖北永瑞生物科技有限公司」 鉅亨網　　2012-05-04    第七條　第8款  1.契約終止日期:101/05/04   2.契約內容:原本公司與永日化學工業股份有限公司及美國BioResource international Inc於   100/03/28簽訂合資契約轉投資大陸設立湖北永瑞生物科技有限公司。3.契約相對人:永日化學工業股份有限公司及美國 BioResource international Inc.  4.與公司關係:永日化學工業股份有限公司為本公司採權益法評價之投資公司;美國BioResource international Inc.則無。  5.終止之原因:永瑞合資案因三方合資股東對於智財權的保護及擴量生產意見歧異，為免影響公司營運擬予終止合資案。  6.對公司財務、業務之影響:無。7.其他應敘明事項:   經英屬維京群島YungRay Investment Co., Ltd. 101/05/04董事會通過三方合資終止  ，本公司正式與原合資案股東簽署終止合約。

Food Allergies More Common in Kids Born in the Fall

 May 4, 2012 0 Comments  Posted in News, Science & Research, Children, Food Safety, Immunity, Immune Health, Allergens, Food Allergies, Bakery / Cereal, Grains / Pasta / Tuber, Gluten, Soy, Nuts, Peanuts, Fish, Dairy, Milk, Egg, Frozen / Refrigerated Foods, Snack Foods, Beverages, Wheat, Demographic Print BALTIMORE—Johns Hopkins School of Medicine researchers investigating the mechanisms by which season of birth impacts on food allergy risk suggest children born in the fall have a higher risk of food allergies, according to a new study published in the journal Allergy. The study found a significantly increased risk was seen only for Caucasians and those with eczema.  The researchers examined data from 5,862 children in the National Health and Nutrition Examination Survey (NHANES) III and 1,514 children with food allergies from the Johns Hopkins Pediatric Allergy Clinic (JHPAC). They found fall birth is associated with increased risk of food allergy, and the risk is greatest among those most likely to have seasonal variation in vitamin D during infancy (Caucasians) and those at risk for skin barrier dysfunction (subjects with a history of eczema), suggesting that vitamin D and the skin barrier may be implicated in seasonal associations with food allergy.  The findings support research recently conducted at the Albert Einstein College of Medicine of Yeshiva University that found children with low levels of vitamin D have a greater risk of developing food allergies.

Microfluidic device designed to cleanse blood

By Ben Coxworth  15:47 May 4, 2012  In a natural phenomenon known as margination, platelets and leukocytes (white blood cells) within the bloodstream move towards the sides of blood vessels and adhere to them. It occurs at wound sites, during the early stages of inflammation. Recently, a team of researchers from the Massachusetts Institute of Technology and the National University of Singapore have put that process to work in a microfluidic device that could be used to cleanse the blood, perhaps acting as a treatment for bacteria-related blood disorders such as sepsis.  The device consists of a polymer chip, with a network of microchannels etched onto its surface. These channels are made using technology utilized in the manufacturing of integrated circuits, and each measure just 20 micrometers in height and width.  Initially, bacterially-infected blood flows into the device through a single channel. As it flows, the margination process causes the microbes, leukocytes, and platelets within it to move to the sides of the channel, while the red blood cells stay in the middle. Farther down the device, however, two sub-channels branch off from either side. The unwanted cells are diverted into these side channels, while the red blood cells continue following the main one. Farther down still, another two sub-channels branch off again, to remove bacteria that didn't take one of the previous exit ramps.     Theoretically, the purified red blood cells could then be returned into the patient. While it might take quite a while to treat a human using a single microchannel network, the team has also tried out a larger version of the device, in which six networks run simultaneously.  In blood samples tested so far, the scientists have successfully removed 80 and 90 percent of the bacteria Escherichia coli and Saccharomyces cerevisiae, respectively. They have also been able to remove over 80 percent of the blood's inflammatory cellular components – sepsis occurs as an inflammatory response to bacteria in the bloodstream.  MIT's Jongyoon Han pointed out to us that the team has not actually used the device to treat sepsis ... yet. Tests on lab mice, however, are now beginning.  Source: American Institute of Physics